XOMA Corporation XOMA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Income Not From Contract With Customer Cost Recovery Method by Product | ||||||
| Tovorafenib | $10.96M+25.6% | $13.72M+328% | $10.39M— | $9.57M— | $8.73M— | |
| Income Not From Contract With Customer Effective Interest Rate Method by Product | ||||||
| Ixinity | $982K+117% | $989K+272% | $807.5K— | $635K— | $452.5K— | |
| Miplyffa | $3.65M— | $1.8M— | —— | —— | —— | |
| Vabysmo | $24.84M+20.5% | $23.96M+61.9% | $23.11M— | $21.81M— | $20.62M— | |
| Rights Receivable Eir Method Receipt Of Payments by Product | ||||||
| Ixinity | $1.64M— | $1.72M— | —— | —— | —— | |
| Miplyffa | $1.75M— | $908K— | —— | —— | —— | |
| Revenue by Geography | ||||||
| CH | $24.84M+29.8% | $23.96M+61.9% | $23.11M— | $21.81M— | $19.13M— | |
| US | $22.62M+35.7% | $23.09M+91.4% | $18.37M+71.6% | $17.52M+78.0% | $16.67M+294% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does XOMA Corporation break its business down?
- XOMA Corporation (XOMA) reports income not from contract with customer cost recovery method by product across 2 parts — Dsuvia and Tovorafenib. Each is extracted from the segment footnotes and tracked over time.
- Where does XOMA Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in XOMA Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
